Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria

Clinical Infectious Diseases

Volumn 37, Issue 1, 2003, Pages 7-16

  Newton, Paul N ^a,d   Angus, Brian J ^a,d   Chierakul, Wirongrong ^a   Dondorp, Arjen ^a,d   Ruangveerayuth, Ronatrai ^c   Silamut, Kamolrat ^a   Teerapong, Pramote ^a   Suputtamongkol, Yupin ^b   Looareesuwan, Sornchai ^a   White, Nicholas J ^a,d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MAE SOT GENERAL HOSPITAL   (Thailand)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; BILIRUBIN; DOXYCYCLINE; LACTIC ACID; MEFLOQUINE; QUININE; TETRACYCLINE;

ADOLESCENT; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CINCHONISM; COMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; CONVALESCENCE; DEATH; DISEASE SEVERITY; DRUG EFFICACY; ERYTHEMA; FEMALE; GLASGOW COMA SCALE; HOSPITAL; HOSPITAL ADMISSION; HUMAN; HYPOGLYCEMIA; LACTATE BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MORTALITY; MULTIPLE REGRESSION; NEUROPSYCHIATRIC REACTION; PARASITE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZATION; RISK; RISK FACTOR; SIDE EFFECT; THAILAND; URTICARIA;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; ARTEMISININS; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; QUININE; SESQUITERPENES; SURVIVAL ANALYSIS; THAILAND; TREATMENT OUTCOME;

EID: 0037897459     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/375059     Document Type: Article

References (50)

1. White NJ, Warrell DA, Chanthavanich P, et al. Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med 1983; 309:61-6.
2. White NJ. The treatment of malaria. N Engl J Med 1996; 335:800-6.
3. World Health Organization. Severe and complicated malaria. Trans R Soc Trop Med Hyg 1990; 84(Suppl 2):1-65.
4. Pukrittayakamee S, Supanaranond W, Looareesuwan S, Vanijanonta S, White NJ. Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Trans R Soc Trop Med Hyg 1994; 88:324-7.
5. Pinswadi K, Chaereonkwan P. Sluggish response of a case of falciparum malaria to intensive quinine therapy. J Med Assoc Thai 1965; 48:386.
6. Clyde DF, Miller RM. Treatment of falciparum malaria caused by strains resistant to quinine. JAMA 1970; 213:2041-5.
7. Jaroovesma N, Harinasuta T, Muangmanee L. Recrudescence, poor response or resistance to quinine of falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health 1974; 5:504-9.
8. Giboda M, Denis MB. Response of Kampuchean strains of Plasmodium falciparum to antimalarials. In vivo assessment of quinine and quinine plus tetracycline: multiple drug resistance in vitro. J Trop Med Hyg 1988; 91:205-11.
9. Looareesuwan S, Charoenpan P, Ho M, et al. Fatal Plasmodium falciparum malaria after an inadequate response to quinine treatment. J Infect Dis 1990; 161:577-80.
10. Li GQ, Guo XB, Jin R, Wang ZC, Jian HX, Li ZY. Clinical studies on treatment of cerebral malaria with qinghaosu and its derivatives. J Tradit Chin Med 1982; 2:125-30.
11. Hien TT, White NJ. Qinghaosu. Lancet 1993; 341:603-8.
12. Li Y, Wu Y-L. How Chinese scientists discovered quinhaosu (artemisinin) and developed its derivatives? What are the future perspectives? Med Trop (Mars) 1998; 58(Suppl):9-12.
13. Meshnick SR, Taylor TE, Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 1996; 60:301-15.
14. Van Agtmael MA, Eggelte TA, van Boxtel CJ. Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. Trends Pharmacol Sci 1999; 20:199-205.
15. Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000; 356:297-302.
16. Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996; 347:1654-8.
17. Barradell LB, Fitton A. Artesunate. Drugs 1995; 50:714-41.
18. Newton PN, Suputtamongkol Y, Teja-Isavadharm P, et al. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44:972-7.
19. Price RN, van Vugt M, Nosten F, et al. Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria. Am J Trop Med Hyg 1998; 59:883-8.
20. Hien TT, Day NPJ, Phu NH, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335:76-83.
21. Murphy SA, English M, Waruiru C, et al. An open randomized trial of artemether versus quinine in the treatment of cerebral malaria in African children. Trans R Soc Trop Med Hyg 1996; 90:298-301.
22. Van Hensbroek MB, Onyiorah E, Jaffer S, et al. A trial of artemether or quinine in children with cerebral malaria. N Engl J Med 1996; 335:69-75.
23. Thuma PE, Bhat GJ, Mabeza GF, et al. A randomised controlled trial of artemotil (β-arteether) in Zambian children with cerebral malaria. Am J Trop Med Hyg 2000; 62:524-9.
24. Pittler MH, Ernst E. Artemether for severe malaria. Clin Infect Dis 1999; 28:597-601.
25. A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Artemether-Quinine Meta-analysis Study Group. Trans R Soc Trop Med Hyg 2001; 95:637-50.
26. Moyou-Somo R, Tietche F, Ondona M, et al. Clinical trial of β-arteether versus quinine for the treatment of cerebral malaria in children in Yaounde, Cameroon. Am J Trop Med Hyg 2001; 64:229-32.
27. Phuong CXT, Bethell DB, Phuong PT, et al. Comparison of artemisinin suppositories, intramuscular artesunate and intravenous quinine for the treatment of severe childhood malaria. Trans R Soc Trop Med Hyg 1997; 91:335-42.
28. Hien TT, Phu NH, Mai NTH, et al. An open randomised comparison of intravenous and intramuscular artesunate in severe falciparum malaria. Trans R Soc Trop Med Hyg 1992; 86:584-5.
29. Win K, Than M, Thwe Y. Comparsion of combinations of parenteral artemisinin derivatives plus oral mefloquine with intravenous quinine plus oral tetracycline for treating cerebral malaria. Bull World Health Organ 1992; 70:777-82.
30. Teja-Isavadharm P, Nosten F, Kyle DE, et al. Comparative bioavailability of oral, rectal and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. Br J Clin Pharmacol 1996; 42:599-604.
31. Murphy SA, Mberu E, Muhia D, et al. The disposition of intramuscular artemether in children with cerebral malaria: a preliminary study. Trans R Soc Trop Med Hyg 1997; 91:331-4.
32. Brockman A, Price RN, van Vugt M, et al. Plasmodium falciparum antimalarial drug susceptibility on the northwestern border of Thailand during five years of extensive artesunate-mefloquine use. Trans R Soc Trop Med Hyg 2000; 94:537-44.
33. Nontprasert A, Nosten-Bertrand M, Pukrittayakamee S, Vanijanonta S, Angus BJ, White NJ. Assessment of the neurotoxicity of parenteral artemisinin derivatives in mice. Am J Trop Med Hyg 1998; 59:519-22.
34. Price RN, van Vugt M, Phaipun L, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 1999; 60:547-50.
35. Luxemburger C, Ricci F, Nosten F, Raimond D, Bathet S, White NJ. The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg 1997; 91:256-62.
36. Mai NTH, Day NPJ, Chuong LV, et al. Post-malaria neurological syndrome. Lancet 1996; 348:917-21.
37. Silamut K, White NJ. Relation of the stage of parasite development in the peripheral blood to prognosis in severe falciparum malaria. Trans R Soc Trop Med Hyg 1993; 87:436-43.
38. Silamut K, Hough R, Eggelte T, Pukrittayakamee S, Angus B, White NJ. A simple method for assessing quinine pre-treatment in acute malaria. Trans R Soc Trop Med Hyg 1995; 89:665-7.
39. White NJ. Assessment of the pharmacodynamic properties of anti-malarial drugs in-vivo. Antimicrob Agents Chemother 1997; 41:1413-22.
40. Angus BJ, Chotivanich K, Udomsangpetch R, White NJ. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood 1997; 90:2037-40.
41. Dondorp AM, Angus BJ, Hardeman MR, et al. Prognostic significance of reduced red cell deformability in severe falciparum malaria. Am J Trop Med Hyg 1997; 57:507-11.
42. Newton PN, Chotivanich K, Chierakul W, et al. A comparison of the in vivo kinetics of Plasmodium falciparum ring-infected erythrocyte surface antigen (RESA) positive and negative erythrocytes. Blood 2001; 98:450-7.
43. World Health Organization. Chemotherapy of malaria and resistance to antimalarials: report of a WHO scientific group. World Health Organ Tech Rep Ser 1973; 529:1-121.
44. Seguro AC, Campos SB. Diuretic effect of sodium artesunate in patients with malaria. Am J Trop Med Hyg 2002; 67:473-4.
45. Leonardi E, Gilvary G, White NJ, Nosten F. Severe allergic reaction to oral artesunate: a report of two cases. Trans R Soc Trop Med Hyg 2001; 95:182-3.
46. Miller LG, Panosian CB. Ataxia and slurred speech after artesunate treatment for falciparum malaria. N Engl J Med 1997; 336:1328.
47. Elias Z, Bonnet E, Marchou B, Massip P. Neurotoxicity of artemisinins: possible counseling and treatment of side effects. Clin Infect Dis 1999; 28:1330-1.
48. Davis TME, Edwards GO, McCarthy JS. Artesunate and cerebellar dysfunction in falciparum malaria. N Engl J Med 1997; 337:792.
49. White NJ. Neurological dysfunction following malaria: disease- or drug-related [letter]? Clin Infect Dis 2000; 30:836.
50. Newton PN, White NJ. Malaria: new developments in treatment and prevention. Annu Rev Med 1999; 50:179-92.